Janney Montgomery Scott LLC Trims Stock Position in Charles River Laboratories International, Inc. $CRL

Janney Montgomery Scott LLC cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 38.1% in the first quarter, HoldingsChannel reports. The firm owned 12,388 shares of the medical research company’s stock after selling 7,640 shares during the period. Janney Montgomery Scott LLC’s holdings in Charles River Laboratories International were worth $2,137,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in CRL. Tema Etfs LLC purchased a new stake in Charles River Laboratories International in the 4th quarter worth approximately $26,000. Los Angeles Capital Management LLC acquired a new position in Charles River Laboratories International in the 4th quarter worth about $42,000. Sfam LLC purchased a new position in Charles River Laboratories International during the fourth quarter worth approximately $43,000. Activest Wealth Management increased its position in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in Charles River Laboratories International in the 4th quarter valued at $46,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. This represents a 70.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Price Performance

CRL stock opened at $224.07 on Thursday. The business’s fifty day moving average price is $185.01 and its 200 day moving average price is $185.28. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $236.62. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $10.79 billion, a PE ratio of -59.59, a P/E/G ratio of 2.61 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on CRL shares. Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research note on Friday, May 8th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.